Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43901021" target="_blank" >RIV/00216208:11120/12:43901021 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/12:43901021

Result on the web

<a href="http://dx.doi.org/10.1038/pcan.2012.18" target="_blank" >http://dx.doi.org/10.1038/pcan.2012.18</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/pcan.2012.18" target="_blank" >10.1038/pcan.2012.18</a>

Result language

angličtina

Original language name

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

Original language description

Background: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. Methods: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measure

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Prostate Cancer and Prostatic Diseases

ISSN

1365-7852

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

3

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

308-312

UT code for WoS article

000307799300016

EID of the result in the Scopus database

—